2021 Pipeline Insight Report on Interstitial Lung Diseases – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Interstitial Lung Diseases – Pipeline Insight, 2021” has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Lung Disease R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.

Interstitial Lung Disease Emerging Drugs Chapters

This segment of the Interstitial Lung Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interstitial Lung Disease Emerging Drugs

AD-214: AdAlta

AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. At the back end of AD-214 is the Fc Fragment or tail region of a traditional monoclonal antibody that will extend the half-life or duration of time in which the i-body will stay in the body. Currently it is in phase 1 stage of development for the treatment of interstitial lung disease.

Abatacept: Bristol-Myers Squibb

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Currently, it is in phase 2 stage of development for the treatment of interstitial lung disease.

ATYR1923: aTyr Pharma

ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung

Interstitial Lung Disease: Therapeutic Assessment

This segment of the report provides insights about the different Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interstitial Lung Disease

There are approx. 100+ key companies which are developing the therapies for Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e. phase II include, Bristol-Myers Squibb.

Phases

This report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Key Players

• AdAlta
• Bristol-Myers Squibb
• aTyr Pharma
• Avalyn Pharmaceuticals
• Beijing Continent Pharmaceutical
• Regend Therapeutics
• Reata Pharmaceuticals
• FibroGen
• PureTech Health
• Bellerophon Pulse Technologies
• OncoArendi Therapeutics
• LTT Bio-Pharma
• EmphyCorp
• Genentech
• Blade Therapeutics
• Acceleron Pharma

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/h9p9nu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900